New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
MedPage Today23h
FDA Approves First Novel Drug for Schizophrenia in Decades
The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of ...
Monthly Prescribing Reference1d
IDSA 2024 Guidance on Antimicrobial-Resistant Gram-Negative Infections
The Infectious Diseases Society of America aimed to develop up-to-date guidance focusing on the treatment of antimicrobial-resistant gram-negative infections.
Yahoo1d
Ozempic Drug Interactions You Should Know: How Common Medications Can Affect Semaglutide Users
When we talk about GLP-1 medications, we’re usually focused on weight loss or the drug’s side effects (we’re looking ...
Business Wire13h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Everyday Health16h
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...